Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 12:45 p.m. ET.
A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event.
About Generation Bio
Generation Bio is innovating non-viral genetic medicines to provide durable and redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). With these platforms, Generation Bio aims to develop the next wave of non-viral genetic medicines to support its mission to extend the reach of genetic medicine to more people living with more diseases, around the world.
For more information, please visit .
Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638
CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 12:45 p.m. ET.
馬薩諸塞州劍橋，2024 年 4 月 2 日（環球新聞專線）— 世代生物公司 納斯達克股票代碼：GBIO）是一家爲罕見和流行病患者創新基因藥物的生物技術公司，該公司宣佈，總裁兼首席執行官傑夫·麥克唐納醫學博士將在美國東部時間2024年4月9日星期二下午 12:45 參加第23屆Needham年度虛擬醫療會議的爐邊談話。
A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event.
該演示文稿的網絡直播將在公司網站的投資者專區播出 投資者 generationbio.com。活動結束後的30天內將在那裏重播。
About Generation Bio
關於世代生物
Generation Bio is innovating non-viral genetic medicines to provide durable and redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). With these platforms, Generation Bio aims to develop the next wave of non-viral genetic medicines to support its mission to extend the reach of genetic medicine to more people living with more diseases, around the world.
Generation Bio正在創新非病毒基因藥物，爲數億患有罕見和流行疾病的患者提供耐用和可重複劑量的治療。該公司正在開發兩個截然不同的互補平台：一種強大的、高選擇性的細胞靶向脂質納米顆粒（cTLnP）輸送系統和一種新型免疫靜默DNA（iQDNA）貨物，該貨物通過可擴展的無殼製造工藝生產，該工藝使用專有的無細胞快速酶促合成（RES）。藉助這些平台，Generation Bio旨在開發下一波非病毒基因藥物，以支持其使命，將基因醫學的覆蓋範圍擴大到全球更多患有更多疾病的人。
For more information, please visit .
欲了解更多信息，請訪問。
Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638
投資者和媒體聯繫人
瑪倫·基拉基
生物世代
mkillackey@generationbio.com
857-371-4638
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧